Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Sausville, EA' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 123 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Woo, EW; Messmann, R; Sausville, EA; Figg, WD
      Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry

      JOURNAL OF CHROMATOGRAPHY B
    2. Roy, KK; Sausville, EA
      Early development of cyclin dependent kinase modulators

      CURRENT PHARMACEUTICAL DESIGN
    3. Sausville, EA
      Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequenceand tumor biology matters - Commentary re: P. Munster et al., modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res., 7: 2228-2236, 2001.

      CLINICAL CANCER RESEARCH
    4. Dudkin, L; Dilling, MB; Cheshire, PJ; Harwood, FC; Hollingshead, M; Arbuck, SG; Travis, R; Sausville, EA; Houghton, PJ
      Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition

      CLINICAL CANCER RESEARCH
    5. Kahn, MES; Senderowicz, A; Sausville, EA; Barrett, KE
      Possible mechanisms of diarrheal side effects associated with the use of anovel chemotherapeutic agent, flavopiridol

      CLINICAL CANCER RESEARCH
    6. Searle, F; Gac-Breton, S; Keane, R; Dimitrijevic, S; Brocchini, S; Sausville, EA; Duncan, R
      N-(2-hydroxypropyl)methacrylamide copolymer-6-(3-aminopropyl)-ellipticine conjugates. Synthesis, in vitro, and preliminary in vivo evaluation

      BIOCONJUGATE CHEMISTRY
    7. Sausville, EA; Arbuck, SG; Messmann, R; Headlee, D; Bauer, KS; Lush, RM; Murgo, A; Figg, WD; Lahusen, T; Jaken, S; Jing, XX; Roberge, M; Fuse, E; Kuwabara, T; Senderowicz, AM
      Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms

      JOURNAL OF CLINICAL ONCOLOGY
    8. Sausville, EA
      Scientific summation and future goals

      JOURNAL OF CONTROLLED RELEASE
    9. Hagenauer, B; Salamon, A; Thalharmmer, T; Kunst, O; Haslinger, E; Klingler, P; Senderoqwicz, AM; Sausville, EA; Jager, W
      In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: Involvement of udpglucuronosyltransferases 1A1 and 1A9

      DRUG METABOLISM AND DISPOSITION
    10. Yu, LJ; Matias, J; Scudiero, DA; Hite, KM; Monks, A; Sausville, EA; Waxman, DJ
      P450 enzyme expression patterns in the NCI human tumor cell line panel

      DRUG METABOLISM AND DISPOSITION
    11. Newton, DL; Kaur, G; Rhim, JS; Sausville, EA; Rybak, SM
      RNA damage and inhibition of neoplastic endothelial cell growth: Effects of human and amphibian ribonucleases

      RADIATION RESEARCH
    12. Bai, RL; Verdier-Pinard, P; Gangwar, S; Stessman, CC; McClure, KJ; Sausville, EA; Pettit, GR; Bates, RB; Hamel, E
      Dolastatin 11, a marine depsipeptide, arrests cells at cytokinesis and induces hyperpolymerization of purified actin

      MOLECULAR PHARMACOLOGY
    13. Lee, BI; Park, SH; Kim, JW; Sausville, EA; Kim, HT; Nakanishi, O; Trepel, JB; Kim, SJ
      MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells

      CANCER RESEARCH
    14. Johnson, JI; Decker, S; Zaharevitz, D; Rubinstein, LV; Venditti, J; Schepartz, S; Kalyandrug, S; Christian, M; Arbuck, S; Hollingshead, M; Sausville, EA
      Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

      BRITISH JOURNAL OF CANCER
    15. Sausville, EA
      Use of immunotoxins in the treatment of lymphoma

      CANCER JOURNAL
    16. Tudor, G; Aguilera, A; Halverson, DO; Laing, ND; Sausville, EA
      Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-x(L) protein levels

      CELL DEATH AND DIFFERENTIATION
    17. Messmann, RA; Vitetta, ES; Headlee, D; Senderowicz, AM; Figg, WD; Schindler, J; Michiel, DF; Creekmore, S; Steinberg, SM; Kohler, D; Jaffe, ES; Stetler-Stevenson, M; Chen, HC; Ghetie, V; Sausville, EA
      A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma

      CLINICAL CANCER RESEARCH
    18. Frankel, AE; Kreitman, RJ; Sausville, EA
      Targeted toxins

      CLINICAL CANCER RESEARCH
    19. Svingen, PA; Tefferi, A; Kottke, TJ; Kaur, G; Narayanan, VL; Sausville, EA; Kaufmann, SH
      Effect of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro

      CLINICAL CANCER RESEARCH
    20. Scherf, U; Ross, DT; Waltham, M; Smith, LH; Lee, JK; Tanabe, L; Kohn, KW; Reinhold, WC; Myers, TG; Andrews, DT; Scudiero, DA; Eisen, MB; Sausville, EA; Pommier, Y; Botstein, D; Brown, PO; Weinstein, JN
      A gene expression database for the molecular pharmacology of cancer

      NATURE GENETICS
    21. Kunick, C; Schultz, C; Lemcke, T; Zaharevitz, DW; Gussio, R; Jalluri, RK; Sausville, EA; Leost, M; Meijer, L
      2-substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    22. Keskin, O; Bahar, I; Jernigan, RL; Beutler, JA; Shoemaker, RH; Sausville, EA; Covell, DG
      Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structure

      ANTI-CANCER DRUG DESIGN
    23. Sausville, EA
      Protein kinase antagonists: interim challenges and issues

      ANTI-CANCER DRUG DESIGN
    24. Gussio, R; Zaharevitz, DW; McGrath, CF; Pattabiraman, N; Kellogg, GE; Schultz, C; Link, A; Kunick, C; Leost, M; Meijer, L; Sausville, EA
      Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition

      ANTI-CANCER DRUG DESIGN
    25. Monks, A; Harris, ED; Vaigro-Wolff, A; Hose, CD; Connelly, JW; Sausville, EA
      UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines

      INVESTIGATIONAL NEW DRUGS
    26. Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Endicott, JA; Garman, EF; Gibson, AE; Golding, BT; Grant, S; Griffin, RJ; Jewsbury, P; Johnson, LN; Lawrie, AM; Newell, DR; Noble, MEM; Sausville, EA; Schultz, R; Yu, W
      Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles

      JOURNAL OF MEDICINAL CHEMISTRY
    27. Graves, PR; Yu, LJ; Schwarz, JK; Gales, J; Sausville, EA; O'Connor, PM; Piwnica-Worms, H
      The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

      JOURNAL OF BIOLOGICAL CHEMISTRY
    28. Chao, SH; Fujinaga, K; Marion, JE; Taube, R; Sausville, EA; Senderowicz, AM; Peterlin, BM; Price, DH
      Flavopiridol inhibits P-TEFb and blocks HIV-1 replication

      JOURNAL OF BIOLOGICAL CHEMISTRY
    29. Kamishohara, M; Kenney, S; Domergue, R; Vistica, DT; Sausville, EA
      Selective accumulation of the endoplasmic reticulum-Golgi intermediate compartment induced by the antitumor drug KRN5500

      EXPERIMENTAL CELL RESEARCH
    30. Leost, M; Schultz, C; Link, A; Wu, YZ; Biernat, J; Mandelkow, EM; Bibb, JA; Snyder, GL; Greengard, P; Zaharevitz, DW; Gussio, R; Senderowicz, AM; Sausville, EA; Kunick, C; Meijer, L
      Paullones are potent inhibitors of glycogen synthase kinase-3 beta and cyclin-dependent kinase 5/p25

      EUROPEAN JOURNAL OF BIOCHEMISTRY
    31. Chua, MS; Kashiyama, E; Bradshaw, TD; Stinson, SF; Brantley, E; Sausville, EA; Stevens, MFG
      Role of CYP1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells

      CANCER RESEARCH
    32. Sausville, EA; Johnson, JI
      Molecules for the millennium: how will they look? New drug discovery year 2000

      BRITISH JOURNAL OF CANCER
    33. Senderowicz, AM; Sausville, EA
      Preclinical and clinical development of cyclin-dependent kinase modulators

      JOURNAL OF THE NATIONAL CANCER INSTITUTE
    34. Sausville, EA
      Dragons 'round the fleece again: STI571 versus alpha 1 acid glycoprotein

      JOURNAL OF THE NATIONAL CANCER INSTITUTE
    35. Mandler, R; Wu, CC; Sausville, EA; Roettinger, AJ; Newman, DJ; Ho, DK; King, CR; Yang, DJ; Lippman, ME; Landolfi, NF; Dadachova, E; Brechbiel, MW; Waldmann, TA
      Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: Antiproliferative activity on human breast carcinoma cell lines

      JOURNAL OF THE NATIONAL CANCER INSTITUTE
    36. Senderowicz, AM; Sausville, EA
      Re: Preclinical and clinical development of cyclin-dependent kinase modulators - Response

      JOURNAL OF THE NATIONAL CANCER INSTITUTE
    37. Sausville, EA; Senderowicz, AM
      Chemical cyclin-dependent kinase inhibitors - Therapeutic implications

      SIGNALING NETWORKS AND CELL CYCLE CONTROL
    38. Sausville, EA; Feigal, E
      Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA

      ANNALS OF ONCOLOGY
    39. Sausville, EA; Zaharevitz, D; Gussio, R; Meijer, L; Louarn-Leost, M; Kunick, C; Schultz, R; Lahusen, T; Headlee, D; Stinson, S; Arbuck, SG; Senderowicz, A
      Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target

      PHARMACOLOGY & THERAPEUTICS
    40. Senderowicz, AM; Reid, R; Headlee, D; Abornathy, T; Horti, J; Lush, RM; Reed, E; Figg, WD; Sausville, EA
      A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer

      UROLOGIA INTERNATIONALIS
    41. Cragg, GM; Boyd, MR; Khanna, R; Kneller, R; Mays, TD; Mazan, KD; Newman, DJ; Sausville, EA
      International collaboration in drug discovery and development: the NCI experience

      PURE AND APPLIED CHEMISTRY
    42. Nieves-Neira, W; Rivera, MI; Kohlhagen, G; Hursey, ML; Pourquier, P; Sausville, EA; Pommier, Y
      DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells

      MOLECULAR PHARMACOLOGY
    43. Kashiyama, E; Hutchinson, I; Chua, MS; Stinson, SF; Phillips, LR; Kaur, G; Sausville, EA; Bradshaw, TD; Westwell, AD; Stevens, MFG
      Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles

      JOURNAL OF MEDICINAL CHEMISTRY
    44. Schultz, C; Link, A; Leost, M; Zaharevitz, DW; Gussio, R; Sausville, EA; Meijer, L; Kunick, C
      Paullones, a series of cyclin-dependent kinase inhibitors: Synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity

      JOURNAL OF MEDICINAL CHEMISTRY
    45. Schnier, JB; Kaur, G; Kaiser, A; Stinson, SF; Sausville, EA; Gardner, J; Nishi, K; Bradbury, EM; Senderowicz, AM
      Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein

      FEBS LETTERS
    46. Melillo, G; Sausville, EA; Cloud, K; Lahusen, T; Varesio, L; Senderowicz, AM
      Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic inductionof vascular endothelial growth factor expression in human monocytes

      CANCER RESEARCH
    47. Carlson, B; Lahusen, T; Singh, S; Loaiza-Perez, A; Worland, PJ; Pestell, R; Albanese, C; Sausville, EA; Senderowicz, AM
      Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol

      CANCER RESEARCH
    48. Zaharevitz, DW; Gussio, R; Leost, M; Senderowicz, AM; Lahusen, T; Kunick, C; Meijer, L; Sausville, EA
      Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases

      CANCER RESEARCH
    49. Adams, J; Palombella, VJ; Sausville, EA; Johnson, J; Destree, A; Lazarus, DD; Maas, J; Pien, CS; Prakash, S; Elliott, PJ
      Proteasome inhibitors: A novel class of potent and effective antitumor agents

      CANCER RESEARCH
    50. Losiewicz, MD; Kaur, G; Sausville, EA
      Different early effects of tyrphostin AG957 and geldanamycins on mitogen-activated protein kinase and p120(cbl) phosphorylation in anti CD-3-stimulated T-lymphoblasts

      BIOCHEMICAL PHARMACOLOGY
    51. Rivera, MI; Stinson, SF; Vistica, DT; Jorden, JL; Kenney, S; Sausville, EA
      Selective toxicity of the tricyclic thiophene NSC652287 in renal carcinomacell lines - Differential accumulation and metabolism

      BIOCHEMICAL PHARMACOLOGY
    52. Sausville, EA
      A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: A promising path for progress emerges

      JOURNAL OF THE NATIONAL CANCER INSTITUTE
    53. CONLEY BA; EGORIN MJ; TAIT N; ROSEN DM; SAUSVILLE EA; DOVER G; FRAM RJ; VANECHO DA
      PHASE-I STUDY OF THE ORALLY-ADMINISTERED BUTYRATE PRODRUG, TRIBUTYRIN, IN PATIENTS WITH SOLID TUMORS

      Clinical cancer research
    54. CONLEY BA; EGORIN MJ; TAIT N; ROSEN DM; SAUSVILLE EA; DOVER G; FRAM RJ; VANECHO DA
      PHASE-I STUDY OF THE ORALLY-ADMINISTERED BUTYRATE PRODRUG, TRIBUTYRIN, IN PATIENTS WITH SOLID TUMORS

      Clinical cancer research
    55. SAUSVILLE EA; HEADLEE D; STINSON SF; LUSH RM; FIGG WD; ARBUCK SG; SENDEROWICZ AM
      CYCLIN-DEPENDENT KINASES - TARGETS FOR NOVEL THERAPEUTIC APPROACHES

      Annals of oncology
    56. HENDRIKS HR; BURTLES S; RADTKE S; SCHULTZ RJ; DOUBLE JA; SAUSVILLE EA; NEWELL DR
      CELL-BASED SCREENING AND PHARMACOLOGICAL STRATEGIES FOR THE SELECTIONOF NEW ANTICANCER AGENTS - A COLLABORATION BETWEEN THE NATIONAL-CANCER-INSTITUTE (NCI), CANCER-RESEARCH CAMPAIGN (CRC) AND EORTC

      Annals of oncology
    57. CHUA MS; SAUSVILLE EA; HUTCHINSON I; BRADSHAW TD; STEVENS MFG
      PRECLINICAL STUDIES ON 2-(4-AMINO-3-METHYLPHENYL)BENZOTHIAZOLE

      Annals of oncology
    58. SENDEROWICZ AM; HEADLEE D; LUSH R; ARBUCK S; BAUER K; FIGG WD; MURGO A; INOUE K; KOBASHI S; KUWABARA T; SAUSVILLE EA
      PHASE-I TRIAL OF INFUSIONAL UCN-01, A NOVEL PROTEIN-KINASE INHIBITOR,IN PATIENTS WITH REFRACTORY NEOPLASMS

      Annals of oncology
    59. BURGER AM; FIEBIG HH; NEWMAN DJ; CAMALIER RF; SAUSVILLE EA
      ANTITUMOR-ACTIVITY OF 17-ALLYLAMINOGELDANAMYCIN (NSC-330507) IN MELANOMA XENOGRAFTS IS ASSOCIATED WITH DECLINE IN HSP90 PROTEIN EXPRESSION

      Annals of oncology
    60. SENDEROWICZ AM; HEADLEE D; STINSON SF; LUSH RM; KALIL N; VILLALBA L; HILL K; STEINBERG SM; FIGG WD; TOMPKINS A; ARBUCK SG; SAUSVILLE EA
      PHASE-I TRIAL OF CONTINUOUS-INFUSION FLAVOPIRIDOL, A NOVEL CYCLIN-DEPENDENT KINASE INHIBITOR, IN PATIENTS WITH REFRACTORY NEOPLASMS

      Journal of clinical oncology
    61. TAKEUCHI H; ARA G; SAUSVILLE EA; TEICHER B
      JASPLAKINOLIDE - INTERACTION WITH RADIATION AND HYPERTHERMIA IN HUMANPROSTATE CARCINOMA AND LEWIS-LUNG-CARCINOMA

      Cancer chemotherapy and pharmacology
    62. SAUSVILLE EA; LUSH RD; HEADLEE D; SMITH AC; FIGG WD; ARBUCK SG; SENDEROWICZ AM; FUSE E; TANII H; KUWABARA T; KOBAYASHI S
      CLINICAL-PHARMACOLOGY OF UCN-01 - INITIAL OBSERVATIONS AND COMPARISONTO PRECLINICAL MODELS

      Cancer chemotherapy and pharmacology
    63. ARGUELLO F; ALEXANDER MA; GREENE JF; STINSON SF; JORDEN JL; SMITH EM; KALAVAR NT; ALVORD WG; KLABANSKY RL; SAUSVILLE EA
      PRECLINICAL EVALUATION OF 9-CHLORO-2-METHYLELLIPTICINIUM ACETATE ALONE AND IN COMBINATION WITH CONVENTIONAL ANTICANCER DRUGS FOR THE TREATMENT OF HUMAN BRAIN-TUMOR XENOGRAFTS

      Journal of cancer research and clinical oncology
    64. BYRD JC; RAI KR; SAUSVILLE EA; GREVER MR
      OLD AND NEW THERAPIES IN CHRONIC LYMPHOCYTIC-LEUKEMIA - NOW IS THE TIME FOR A REASSESSMENT OF THERAPEUTIC GOALS

      Seminars in oncology
    65. Engert, A; Sausville, EA; Vitetta, E
      The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma

      CLINICAL APPLICATIONS OF IMMUNOTOXINS
    66. JAGER W; ZEMBSCH B; WOLSCHANN P; PITTENAUER E; SENDEROWICZ AM; SAUSVILLE EA; SEDLACEK HH; GRAF J; THALHAMMER T
      METABOLISM OF THE ANTICANCER DRUG FLAVOPIRIDOL, A NEW INHIBITOR OF CYCLIN-DEPENDENT KINASES, IN RAT-LIVER

      Life sciences
    67. PATEL V; SENDEROWICZ AM; PINTO D; IGISHI T; RAFFELD M; QUINTANILLAMARTINEZ L; ENSLEY JF; SAUSVILLE EA; GUTKIND JS
      FLAVOPIRIDOL, A NOVEL CYCLIN-DEPENDENT KINASE INHIBITOR, SUPPRESSES THE GROWTH OF HEAD AND NECK SQUAMOUS-CELL CARCINOMAS BY INDUCING APOPTOSIS

      The Journal of clinical investigation
    68. Yu, LJ; Orlandi, L; Wang, P; Orr, MS; Senderowicz, AM; Sausville, EA; Silvestrini, R; Watanabe, N; Piwnica-Worms, H; O'Connor, PM
      UCN-01 abrogates G(2) arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase

      JOURNAL OF BIOLOGICAL CHEMISTRY
    69. RAMIREZ J; IYER L; LUSH RM; MORTELL M; FEUER JA; FIGG WD; SAUSVILLE EA; RATAIN MJ
      IN-VITRO GLUCURONIDATION OF FLAVOPIRIDOL (NSC649890) (FLAVO) BY HUMANLIVER-MICROSOMES

      Clinical pharmacology and therapeutics
    70. FUSE E; TANII H; KURATA N; KOBAYASHI H; SHIMADA Y; TAMURA T; SASAKI Y; TANIGAWARA Y; LUSH RD; HEADLEE D; FIGG WD; ARBUCK SG; SENDEROWICZ AM; SAUSVILLE EA; AKINAGA S; KUWAHARA A; KOBASASHI S
      UNPREDICTED CLINICAL-PHARMACOLOGY OF UCN-01 CAUSED BY SPECIFIC BINDING TO HUMAN ALPHA(1)-ACID GLYCOPROTEIN

      Cancer research
    71. ARGUELLO F; ALEXANDER M; STERRY JA; TUDOR G; SMITH EM; KALAVAR NT; GREENE JF; KOSS W; MORGAN CD; STINSON SF; SIFORD TJ; ALVORD WG; KLABANSKY RL; SAUSVILLE EA
      FLAVOPIRIDOL INDUCES APOPTOSIS OF NORMAL LYMPHOID-CELLS, CAUSES IMMUNOSUPPRESSION, AND HAS POTENT ANTITUMOR-ACTIVITY IN-VIVO AGAINST HUMAN LEUKEMIA AND LYMPHOMA XENOGRAFTS

      Blood
    72. PARKER BW; KAUR G; NIEVESNEIRA W; TAIMI M; KOHLHAGEN G; SHIMIZU T; LOSIEWICZ MD; POMMIER Y; SAUSVILLE EA; SENDEROWICZ AM
      EARLY INDUCTION OF APOPTOSIS IN HEMATOPOIETIC-CELL LINES AFTER EXPOSURE TO FLAVOPIRIDOL

      Blood
    73. KITADA S; KRAJEWSKA M; ZHANG X; SCUDIERO D; ZAPATA JM; WANG HG; SHABAIK A; TUDOR G; KRAJEWSKI S; MYERS TG; JOHNSON GS; SAUSVILLE EA; REED JC
      EXPRESSION AND LOCATION OF PRO-APOPTOTIC BCL-2 FAMILY PROTEIN BAD IN NORMAL HUMAN TISSUES AND TUMOR-CELL LINES

      The American journal of pathology
    74. SCUDIERO DA; MONKS A; SAUSVILLE EA
      CELL-LINE DESIGNATION CHANGE - MULTIDRUG-RESISTANT CELL-LINE IN THE NCI ANTICANCER SCREEN

      Journal of the National Cancer Institute
    75. FREIJE JMP; LAWRENCE JA; HOLLINGSHEAD MG; DELAROSA A; NARAYANAN V; GREVER M; SAUSVILLE EA; PAULL K; STEEG PS
      IDENTIFICATION OF COMPOUNDS WITH PREFERENTIAL INHIBITORY ACTIVITY AGAINST LOW-NM23-EXPRESSING HUMAN BREAST-CARCINOMA AND MELANOMA CELL-LINES

      Nature medicine
    76. RICE WG; TURPIN JA; HUANG MJ; CLANTON D; BUCKHEIT RW; COVELL DG; WALLQVIST A; MCDONNELL NB; DEGUZMAN RN; SUMMERS MF; ZALKOW L; BADER JP; HAUGWITZ RD; SAUSVILLE EA
      AZODICARBONAMIDE INHIBITS HIV-1 REPLICATION BY TARGETING THE NUCLEOCAPSID PROTEIN

      Nature medicine
    77. BURGER AM; KAUR G; HOLLINGSHEAD M; FISCHER RT; NAGASHIMA K; MALSPEIS L; DUNCAN KLK; SAUSVILLE EA
      ANTIPROLIFERATIVE ACTIVITY IN-VITRO AND IN-VIVO OF THE SPICAMYCIN ANALOG KRN5500 WITH ALTERED GLYCOPROTEIN EXPRESSION IN-VITRO

      Clinical cancer research
    78. DREES M; DENGLER WA; ROTH T; LABONTE H; MAYO J; MALSPEIS L; GREVER M; SAUSVILLE EA; FIEBIG HH
      FLAVOPIRIDOL (L86-8275) - SELECTIVE ANTITUMOR-ACTIVITY IN-VITRO AND ACTIVITY IN-VIVO FOR PROSTATE CARCINOMA-CELLS

      Clinical cancer research
    79. MONKS A; HOLLINGSHEAD M; SAUSVILLE EA
      IDENTIFICATION OF NOVEL CHEMICAL CLASSES WITH POTENTIAL UTILITY AGAINST AIDS-RELATED LYMPHOMA

      Journal of acquired immune deficiency syndromes and human retrovirology
    80. DAWSON NA; FIGG WD; COOPER MR; SARTOR O; BERGAN RC; SENDEROWICZ AM; STEINBERG SM; TOMPKINS A; WEINBERGER B; SAUSVILLE EA; REED E; MYERS CE
      PHASE-II TRIAL OF SURAMIN, LEUPROLIDE, AND FLUTAMIDE IN PREVIOUSLY UNTREATED METASTATIC PROSTATE-CANCER

      Journal of clinical oncology
    81. MONKS A; SCUDIERO DA; JOHNSON GS; PAULL KD; SAUSVILLE EA
      THE NCI ANTICANCER DRUG SCREEN - A SMART SCREEN TO IDENTIFY EFFECTORSOF NOVEL TARGETS

      Anti-cancer drug design
    82. MYERS TG; ANDERSON NL; WALTHAM M; LI G; BUOLAMWINI JK; SCUDIERO DA; PAULL KD; SAUSVILLE EA; WEINSTEIN JN
      A PROTEIN EXPRESSION DATABASE FOR THE MOLECULAR PHARMACOLOGY OF CANCER

      Electrophoresis
    83. CHRISTIAN MC; PLUDA JM; HO PTC; ARBUCK SG; MURGO AJ; SAUSVILLE EA
      PROMISING NEW AGENTS UNDER DEVELOPMENT BY THE DIVISION OF CANCER-TREATMENT, DIAGNOSIS, AND CENTERS OF THE NATIONAL-CANCER-INSTITUTE

      Seminars in oncology
    84. WEINSTEIN JN; MYERS TG; OCONNOR PM; FRIEND SH; FORNACE AJ; KOHN KW; FOJO T; BATES SE; RUBINSTEIN LV; ANDERSON NL; BUOLAMWINI JK; VANOSDOL WW; MONKS AP; SCUDIERO DA; SAUSVILLE EA; ZAHAREVITZ DW; BUNOW B; VISWANADHAN VN; JOHNSON GS; WITTES RE; PAULL KD
      AN INFORMATION-INTENSIVE APPROACH TO THE MOLECULAR PHARMACOLOGY OF CANCER

      Science
    85. SHENFELD M; SENDEROWICZ AM; SAUSVILLE EA; BARRETT KE
      A NOVEL CHEMOTHERAPEUTIC AGENT, FLAVOPIRIDOL, MODULATES INTESTINAL EPITHELIAL CHLORIDE SECRETION

      Gastroenterology
    86. SAUSVILLE EA
      THE TYRPHOSTIN AG17 INDUCES APOPTOSIS AND INHIBITION OF CDK2 ACTIVITYIN A LYMPHOMA CELL-LINE THAT OVEREXPRESSES BCL-2

      Cancer research
    87. OCONNOR PM; JACKMAN J; BAE I; MYERS TG; FAN SJ; MUTOH M; SCUDIERO DA; MONKS A; SAUSVILLE EA; WEINSTEIN JN; FRIEND S; FORNACE AJ; KOHN KW
      CHARACTERIZATION OF THE P53 TUMOR-SUPPRESSOR PATHWAY IN CELL-LINES OFTHE NATIONAL-CANCER-INSTITUTE ANTICANCER DRUG SCREEN AND CORRELATIONSWITH THE GROWTH-INHIBITORY POTENCY OF 123 ANTICANCER AGENTS

      Cancer research
    88. MARCANTONIO D; PANASCI LC; HOLLINGSHEAD MG; ALLEY MC; CAMALIER RF; SAUSVILLE EA; DYKES DJ; CARTER CA; MALSPEIS L
      2-CHLOROETHYL-3-SARCOSINAMIDE-1-NITROSOUREA NOVEL CHLOROETHYLNITROSOUREA ANALOG WITH ENHANCED ANTITUMOR-ACTIVITY AGAINST HUMAN GLIOMA XENOGRAFTS

      Cancer research
    89. KITADA S; KRAJEWSKA M; ZHANG X; SCUDIERO D; ZAPATA JM; WANG HG; SHABAIK A; TUDOR G; KRAJEWSKI S; MYERS TG; JOHNSON GS; SAUSVILLE EA; REED JC
      EXPRESSION OF PRO-APOPTOTIC BCL-2 FAMILY PROTEIN BAD IN NORMAL HEMATOLYMPHOID TISSUES AND HUMAN TUMOR LINES

      Blood
    90. SENDEROWICZ AM; VITETTA E; HEADLEE D; GHETIE V; UHR JW; FIGG WD; LUSH RM; STETLERSTEVENSON M; KERSHAW G; KINGMA DW; JAFFE ES; SAUSVILLE EA
      COMPLETE SUSTAINED RESPONSE OF A REFRACTORY, POSTTRANSPLANTATION, LARGE B-CELL LYMPHOMA TO AN ANTI-CD22 IMMUNOTOXIN

      Annals of internal medicine
    91. BALUNA R; SAUSVILLE EA; STONE MJ; STETLERSTEVENSON MA; UHR JW; VITETTA ES
      DECREASES IN LEVELS OF SERUM FIBRONECTIN PREDICT THE SEVERITY OF VASCULAR LEAK SYNDROME IN PATIENTS TREATED WITH RICIN-A CHAIN-CONTAINING IMMUNOTOXINS

      Clinical cancer research
    92. KAUR G; SAUSVILLE EA
      ALTERED PHYSICAL STATE OF P210(BCR-ABL) IN TYRPHOSTIN AG957-TREATED K562 CELLS

      Anti-cancer drugs
    93. VIALLET J; SAUSVILLE EA
      INVOLVEMENT OF SIGNAL-TRANSDUCTION PATHWAYS IN LUNG-CANCER BIOLOGY

      Journal of cellular biochemistry
    94. FATHI Z; WAY JW; CORJAY MH; VIALLET J; SAUSVILLE EA; BATTEY JF
      BOMBESIN RECEPTOR STRUCTURE AND EXPRESSION IN HUMAN LUNG-CARCINOMA CELL-LINES

      Journal of cellular biochemistry
    95. YASUDA SU; SAUSVILLE EA; HUTCHINS JB; KENNEDY T; WOOSLEY RL
      AMIODARONE-INDUCED LYMPHOCYTE TOXICITY AND MITOCHONDRIAL-FUNCTION

      Journal of cardiovascular pharmacology
    96. TURPIN JA; TERPENING SJ; SCHAEFFER CA; YU G; GLOVER CJ; FELSTED RL; SAUSVILLE EA; RICE WG
      INHIBITORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ZINC FINGERS PREVENT NORMAL PROCESSING OF GAG PRECURSORS AND RESULT IN THE RELEASE OF NONINFECTIOUS VIRUS-PARTICLES

      Journal of virology
    97. CARLSON BA; DUBAY MM; SAUSVILLE EA; BRIZUELA L; WORLAND PJ
      FLAVOPIRIDOL INDUCES G(1) ARREST WITH INHIBITION OF CYCLIN-DEPENDENT KINASE (CDK)2 AND CDK4 IN HUMAN BREAST-CARCINOMA CELLS

      Cancer research
    98. STONE MJ; SAUSVILLE EA; FAY JW; HEADLEE D; COLLINS RH; FIGG WD; STETLERSTEVENSON M; JAIN V; JAFFE ES; SOLOMON D; LUSH RM; SENDEROWICZ A; GHETIE V; SCHINDLER J; UHR JW; VITETTA ES
      A PHASE-I STUDY OF BOLUS VERSUS CONTINUOUS-INFUSION OF THE ANTI-CD19 IMMUNOTOXIN, IGG-HD37-DGA, IN PATIENTS WITH B-CELL LYMPHOMA

      Blood
    99. DUNCAN KLK; DUNCAN MD; ALLEY MC; SAUSVILLE EA
      CUCURBITACIN E-INDUCED DISRUPTION OF THE ACTIN AND VIMENTIN CYTOSKELETON IN PROSTATE CARCINOMA-CELLS

      Biochemical pharmacology
    100. WANG QZ; FAN SJ; EASTMAN A; WORLAND PJ; SAUSVILLE EA; OCONNOR PM
      UCN-01, A POTENT ABROGATOR OF G(2) CHECKPOINT FUNCTION IN CANCER-CELLS WITH DISRUPTED P53

      Journal of the National Cancer Institute


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/10/20 alle ore 06:08:42